IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

10/734,731

Confirmation No. : 6798

First Named Inventor

Eberhard WIELE

Filed

December 15, 2003

TC/A.U.

1647

Examiner

C. J. Nichols

Docket No.

029310.52995US

Customer No.

23911

Title

Screening Method Using Bnpi and Dnpi

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R § § 1.97 AND 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the aboveidentified application.

STATEMENT OF RELEVANCE

The relevance of these references to the subject matter of the present invention is given in the specification of the present invention.

The present Information Disclosure Statement is being filed without a Certification under 37 C.F.R. § 1.97(e) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action or Notice of Allowance (whichever is earlier), and therefore a check for the fee of \$180.00 under 37 C.F.R. § 1.17(p) is Please charge any necessary fee or credit any overpayment in attached.

04/14/2005 SZEWDIE1 00000085 10734731

01 FC:1806

180.00 OP

Page 1 of 2

connection with this Information Disclosure Statement to Deposit Account No. 05-1323.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

If necessary, the paper should be considered as a petition for consideration of the Information Disclosure Statement under 37 C.F.R. § 1.97(d)(2) and that the petition fee set forth in 37 C.F.R. § 1.17(i) in accordance with 37 C.F.R. § 1.97(d)(3) should be charged to Deposit Account 05-1323, Attorney Docket No.: 029310.52995US.

April 13, 2005

Respectfully submitted,

J.D. Evans Registration No. 26,269

CROWELL & MORING LLP Intellectual Property Group P.O. Box 14300 Washington, DC 20044-4300 Telephone No.: (202) 624-2500 Facsimile No.: (202) 628-8844

JDE:jjh

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ger the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

APR 1 3 2005

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

 Complete if Known

 Application Number
 10/734,731

 Filing Date
 December 15, 2003

 First Named Inventor
 Eberhard Weihe

 Art Unit
 1647

 Examiner Name
 C. J. Nichols

 Attorney Docket Number
 029310.52995US

			U.S. PATENT	OCUMENTS	
Examiner Initials'	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US- 5,262,311	11-16-1993	Arthur B. Pardee et al.	· igaros · ppos
		US-			

7

		FOREIG	SN PATENT DOC	CUMENTS		
Examiner Initials'	Cite	Foreign Patent Document Country Code ³ –Number ⁴ –Kind Code ⁵ (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	AB	WO 96/34288	10-31-1996	Eli Lilly and Company		

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	AC	DAVID BAUER ET AL., "Identification of Differentially Expressed mRNA Species by an Improved Display Technique (DDRT-PCR)", Nucleic Acids Research, 1993, pp. 4272-4280, Vol .21, No. 18, Oxford University Press				
	AD	CHIH-CHENG CHEN ET AL., "A P2X Purinoceptor Expressed by a Subset of Sensory Neurons", Letters to Nature, October 5, 1995, pp. 428-431, Vol. 377				
	AE	C.E. FIALLOS-ESTRADA ET AL., "Long-Lasting Increase of Nitric Oxide Synthase Immunoreactivity, NADPH-Diaphorase Reaction and c-JUN Co-Expression in Rat Dorsal Root Ganglion Neurons Following Sciatic Nerve Transection", Neuroscience Letters, 1993, pp. 169-173, 150, Elsevier Scientific Publishers Ireland Ltd.				
	AF	V. HÖLLT ET AL., "Prodynorphin Gene Expression is Enhanced in the Spinal Cord of Chronic Arthritic Rats", Neuroscience Letters, 1987, pp. 90-94, Vol. 73, Elsevier Scientific Publishers Ireland Ltd.				

Examiner	Date	
Signature	Considered	•

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

					Complete if Known	
Substitute	for form 1449B/PTO			Application Number	10/734,731	
	INFORMATION DISC	ı osı	IRE	Filing Date	December 15, 2003	
	STATEMENT BY API			First Named Inventor	Eberhard Weihe	<u>-</u>
	STATEMENT DI AL	L. L. C.	-1141	Art Unit	1647	
	(use as many sheets as n	ecessa	ry)	Examiner Name	C. J. Nichols	
Sheet	2	of	7	Attorney Docket Number	029310.52995US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	AG	JI RU-RONG, "Expression of μ -, 6-, and κ -Opioid Receptor-Like Immunoreactivities in Rat Dorsal Root Ganglia after Carrageenan-Induced Inflammation", The Journal of Neuroscience, December 1995, pp. 8156-8166, Vol. 15, No. 12, 1995, Society for Neuroscience	
	АН	KEIKO MAEKAWA, "Expression of μ -and κ - but not δ -, Opiod Receptor mRNAs is Enhanced in the Spiral Dorsal Horn of the Arthritic Rats, Pain, 1995, pp. 365-371, Vol. 64, Elsevier Science B.V.	
	AI	ABDI A. MOHIT ET AL., "p49 ^{3F12} Kinase: A Novel MAP Kinase Expressed in a Subset of Neurons in the Human Nervous System", Neuron, January 1995, pp. 67-78, Vol. 14, Cell Press	
-	AJ	M.A. RUDA ET AL., "In situ Hybridization Histochemistry and Immunocytochemistry Reveal an Increase in Spinal Dynorphin Biosynthesis in a Rat Model of Peripheral Inflammation and Hyperalgesia", Neurobiology, January 1988, pp. 622-626, Vol. 85, Proc. Natl. Acad. Sci., USA	
-	AK	VALERIE M.K. VERGE ET AL., "Marked Increase in Nitric Oxide Synthase mRNA in Rat Dorsal Root Ganglia after Peripheral Axotomy: <i>In situ</i> Hybridization and Functional Studies", Neurobiology, December 1992, pp. 11617-11621, Vol. 89, Proc. Natl. Acad. Sci., USA	
	AL	ANDREW F. WILKS, "Two Putative Protein-Tyrosine Kinases Identified by Application of the Polymerase Chain Reaction", Genetics, March 1989, pp. 1603-1607, Vol. 86, Proc. Natl. Acad. Sci., USA	
	AM	X. ZHANG ET AL., "Marked Increase in Cholecystokinin B Receptor Messenger RNA Levels in Rat Dorsal Root Ganglia After Peripheral Axotomy", Neuroscience, 1993, pp. 227-233, Vol. 57, No. 2, Pergamon Press Ltd., Great Britain	
	AN	ARMEN N. AKOPIAN ET AL., "A Tetrodotoxin –Resistant Voltage-Gated Sodium Channel Expressed by Sensory Neurons", Letters to Nature, January 18, 1996, pp. 257-262, Vol. 379	

Examiner Date . Signature Considered			
Signature Considered Considered	Examiner	Date	,
	Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Complete if Known Substitute for form 1449B/PTO Application Number 10/734,731 December 15, 2003 Filing Date INFORMATION DISCLOSURE First Named Inventor **Eberhard Weihe** STATEMENT BY APPLICANT Art Unit 1647 **Examiner Name** C. J. Nichols (use as many sheets as necessary) 7 Attorney Docket Number 029310.52995US 3 Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	AO	DOMINIQUE BESSE ET AL., "Monoarthritis Induces Complex Changes in μ - , δ -, and κ - Opioid Binding Sites in the Superficial Dorsal Horn of the Rat Spinal Cord", European Journal of Pharmacology, 1992, pp. 123-131, Vol. 223, Elsevier Science Publishers B.V.	
	AP	TERENCE J. CODERRE ET AL., "Contribution of Central Neuroplasticity to Pathological Pain: Review of Clinical and Experimental Evidence", Pain, 1993, pp. 259-285, 52, Elsevier Science Publishers B.V.	
	AQ	DAVID DUBUISSON ET AL., "The Formalin Test: A Quantitative of the Analgesic Effects of Morphine, Meperidine, and Brain Stem Stimulation in Rats and Cats", Pain, 1977, pp. 161-174, Vol. 4, Elsevier/North-Holland Biomedical Press	
	AR	TATSUO FURUKAWA ET AL., "Identification of New Genes Expressed in a Human Erythroleukemia Cell Line", Blood Cells, Molecules and Diseases, 1996, pp. 11-22, Vol. 22, No. 2, Blood Cells Foundation. LaJolla, California, USA	
-	AS	BRIAN E. HAWES ET AL., "Nociceptin (ORL-1) and μ-Opioid Receptors Mediate Mitogen-Activated Protein Kinase Activation in CHO Cells Through a G _i – Coupled Signaling Pathway: Evidence for Distinct Mechanisms of Agonist-Mediated Desensitization", Journal of Neurochemistry, 1998, pp. 1024-1033, Vol. 71, No. 3, Lippincott-Raven Publishers, Philadelphia, PA, USA	
	AT	M. HUBANK ET AL., "Identifying Differences in mRNA Expression by Representational Difference Analysis of cDNA", Nucleic Acids Research, 1994, pp. 5640-5648, Vol. 22, No. 25	
	AU	SVEN KLUSSMANN ET AL., "Mirror-Image RNA that Binds D-Adenosine", Nature Biotechnology, September 1996, pp. 1112-1115, Vol. 14	
	ÄV	LING-YUAN LI ET AL., "The Stimulatory Effect of Opiods on Mitogen-Activated Proteins Kinase in Chinese Hamster Ovary Cells Transfected to Express μ -Opioid Receptors", Molecular Pharmacology, pp. 599-602, Vol. 50, The American Society of Pharmacology and Experimental Therapeutics	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

					Complete if Known	
Substitute	for form 1449B/PTO			Application Number	10/734,731	
	INFORMATION D	ISCLOSI	IRE	Filing Date	December 15, 2003	
	STATEMENT BY			First Named Inventor	Eberhard Weihe	
	STATEMENT	Ari Lio	7171	Art Unit	1647	
	(use as many sheets	as necessa	ny)	Examiner Name	C. J. Nichols	
Sheet	4	of	7	Attorney Docket Number	029310.52995US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	AW	AXEL METHNER ET AL., "A Novel G Protein-Coupled Receptor with Homology to Neuropeptide and Chemoattractant Receptors Expressed During Bone Development", Biochemical and Biophysical Research Communications, 1997, pp. 336-342, Vol. 233, No. 2, Article No. RC976455, Academic Press	
	AX	K. NOGUCHI ET AL., "Gene Regulation in an Ascending Nociceptive Pathway: Inflammation-Induced Increase in Preprotachykinin mRNA in Rat Lamina I Spinal Projection Neurons", The Journal of Neuroscience, July 1992, pp. 2563-2572, Vol. 12, No. 7, Society for Neuroscience	
	AY	A. SOLODKIN ET AL., "Unilateral Hindpaw Inflammation Produces a Bilateral Increase in Nadph-Diaphorase Histochemical Staining in the Rat Lumbar Spinal Cord", Neuroscience, 1992, pp. 495-499, Vol. 51, No. 3, Pergamon Press Ltd., Great Britain	
	AZ	JACKSON S. WAN ET AL., "Cloning Differentially Expressed mRNA's", Nature Biotechnology, December 1996, pp. 1685-1691, Vol. 14	
-	BA	M. ZIMMERMANN ET AL., "Plasticity of the Nervous System at the Systemic, Cellular and Molecular Levels: a Mechanism of Chronic Pain and Hyperalgesia", Progress in Brain Research, 1998, pp. 233-259, Vol. 110, Chapter 18, Elsevier Science B.V.	
	ВВ	HIROSHI BABA ET AL., "Peripheral Inflammation Facilitates Aβ Fiber-Mediated Synaptic Input to the Substantia Gelatinosa of the Adult Rat Spinal Cord", The Journal of Neuroscience, January 15, 1999, pp. 859-867, Vol. 19., No. 2, Society for	
	ВС	JAMES A. BONINI ET AL., "Molecular Cloning and Tissue Expression of a Novel Orphan G Protein-Coupled Receptor from Rat Lung", Biochemical and Biophysical Research Communications, 1997, pp. 190-193, Vol. 234, No. 1, Article No. RC976591, Academic Press	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

		Complete if Known		
Substitute for form 1449B/PTO	Application Number	10/734,731		
	Filing Date	December 15, 2003		
INFORMATION DISCLOSURE	First Named Inventor	Eberhard Weihe		
STATEMENT BY APPLICANT	Art Unit	1647		
	Examiner Name	C. J. Nichols		
(use as many sheets as necessary)	7 Attorney Docket Number	029310.52995US		
Sheet 5 of	Allomey Docket Number			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BD	ANTHONY DICKENSON, "Novel Pharmacological Targets in the Treatment of Pain, Pain Reviews, 1995, pp. 1-12, Vol. 2	
	BE	F. GILLADRON ET AL., "Long Term Increase in CGRP Levels in Rat Spinal Dorsal Horn Following Skin Ultraviolet Irradiation", 1992, pp. 493-496	
	BF	THOMAS HERDEGEN ET AL., "Expression of Nitric Oxide Synthase and Colocalisation with Jun, Fos and Krox Transcription Factors in Spinal Cord Neurons Following Noxious Stimulation of the Rat Hindpaw", Molecular Brain Research, 1994, pp. 245-258, Vol. 22, Elsevier Science B.V.	
	BG	STEPHEN P. HUNT ET AL., "Induction of c-fos- Like Protein in Spinal Cord Neurons Stephen Steph	_
	ВН	L. KUS ET AL., "N-Methyl-D-Aspartate R1 Messenger RNA and [15]MK-801 Binding Decrease in Rat Spinal Cord After Unilateral Hind Paw Inflammation", Neuroscience, 1995, pp. 159-165, Vol. 68, Elsevier Science Ltd., Great Britain	
•	ВІ	PENG LIANG ET AL., "Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction", Science, August 14, 1992, pp. 967-971, Vol. 257	
	BJ	G.J. MICHAEL ET AL., "Nerve Growth Factor Treatment Increases Brain-Derived Neurotrophic Factor Selectivity in TrkA-Expressing Dorsal Root Ganglion Cells and in Their Central Terminations Within the Spinal Cord", The Journal of Neuroscience, November 1, 1997, pp. 8476-8490, Vol. 17, No. 21, Society for Neuroscience	
	ВК	G.MC. POIRIER ET AL., "Screening Differentially Expressed cDNA Clones Obtained by Differential Display Using Amplified RNA", Nucleic Acids Research, 1997, pp. 913-914, Vol. 25, No. 4, Oxford University Press	
	BL	"Overcoming Limitations of the mRNA Differential	

	Date
Examiner	Considered
Signature	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

tonsidered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).
Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO			Complete if Known			
		Application Number	10/734,731			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	December 15, 2003	
				First Named Inventor	Eberhard Weihe	
	STATEMENT DIF			Art Unit	1647	
(use as many sheets as necessary)				Examiner Name	C. J. Nichols	
Sheet	6	of	7	Attorney Docket Number	029310.52995US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	ВМ	VICTOR E. VELCULESCU ET AL., "Serial Analysis of Gene Expression", Science, October 20, 1995, pp. 484-487	
	BN	JOSEPH B. WATSON ET AL., "Differential cDNA Screening Strategies to Identify Novel Stage-Specific Proteins in the Developing Mammalian Brain", Dev. Neurosci., 1993, pp. 77-86, Vol. 15	
	во	CLIFFORD J. WOOLF ET AL., "Peripheral Nerve Injury Triggers Central Spouting of Myelinated Afferents", Nature, January 2, 1992, pp. 75-78, Vol. 355	
	BP	YASUO AIHARA ET AL., "Molecular Cloning of a Novel Brain-Type Na ⁺ -Dependent Inorganic Phosphate Cotransporter", Journal of Neurochemistry, 2000, pp. 2622-2625, Vol. 74, No. 6, Lippincott Williams & Wilkins Inc., Philadelphia, PA, USA	
	BQ	P.G. GUNASEKAR ET AL., "NMDA Receptor Activation Produces Concurrent Generation of Nitric Oxide and Reactive Oxygen Species: Implication for Cell Death", Journal of Neurochemistry, 1995, pp. 2016-2021, Vol. 65, No. 5, Lippincott-Raven Publishers, Philadelphia, PA, USA	
•	BR	JOHN D. LEVINE ET AL., "Intraneuronal Substance P Contributes to the Severity of Experimental Arthritis", Science, November 2, 1984, pp. 547-549	
	BS	YUN FENG ET AL., "Cloning of a Novel Member of the G Protein-Coupled Receptor Family Related to Peptide Receptors ¹ ", Biochemical and Biophysical Research Communications, 1997, pp. 651-654, Vol. 231, No. 3, Article No. RC976161, Academic Press	
	ВТ	OSAMU URAYAMA ET AL., "Coincident Induction of K rev -1/rap 1A, rap 1B and H-ras mRNAs in the Rat Spinal Cord by Noxious Stimulation ^{1,2} ", Molecular Brain Research, 1997, pp. 331-334, Vol. 45, Elsevier Science B.V.	
	BU	T.R. TÖLLE ET AL., Cellular and Subcellular Distribution of NMDAR1 Splice Variant mRNA in Rat Lumbar Spinal Cord Neurons:, 1982, p. S135	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute	e for form 1449B/PTO			Application Number	10/734,731	
	INFORMATION DISC	LOSI	IRE	Filing Date	December 15, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Eberhard Weihe	
	STATEMENT BY AT	. 2.07		Art Unit	1647	
	(use as many sheets as n	ecessar	γ)	Examiner Name	C. J. Nichols	
Sheet	7	of	7	Attorney Docket Number	029310.52995US	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	BV	THOMAS R. TÖLLE, Chronischer Schmerz, 1997, pp. 307-336			
Examiner Signature		Date Considered			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.